ARS Pharmaceuticals (NASDAQ:SPRY) vs. Critical Outcome Technologies (OTCMKTS:COTQF) Critical Review

ARS Pharmaceuticals (NASDAQ:SPRY) and Critical Outcome Technologies (OTCMKTS:COTQF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for ARS Pharmaceuticals and Critical Outcome Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1	1	3	0	2.40
Critical Outcome Technologies	0	0	0	0	0.00

ARS Pharmaceuticals presently has a consensus target price of $28.25, suggesting a potential upside of 196.87%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Critical Outcome Technologies.

Insider and Institutional Ownership

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ARS Pharmaceuticals and Critical Outcome Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28 million	11.21	-$171.30 million	($1.75)	-5.44
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A

Critical Outcome Technologies has lower revenue, but higher earnings than ARS Pharmaceuticals.

Profitability

This table compares ARS Pharmaceuticals and Critical Outcome Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%
Critical Outcome Technologies	N/A	N/A	N/A

Summary

ARS Pharmaceuticals beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.